EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
FocalTherics™ Reports Second Quarter 2026 Financial Results
FocalTherics reported Q2 2026 revenue of $13.2 million, up 39% year-over-year, driven by a 47% increase in U.S. procedure volume and 44% growth in Focal One system sales.
Gross margin improved to 55.6% from 51.1% in the prior year, while the company announced a $40 million public offering expected to close August 14 to bolster its $21.5 million cash position.
Management reiterated full-year revenue guidance of $50.0 million to $54.0 million and highlighted the launch of the first commercial Focal One Endometriosis Program in Europe.